ArticleMolecular and cellular biology1997
Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase.
Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 133 citations in OpenAlex.
- RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors.Cancers · 2022Article
- Identification of Nanog as a novel inhibitor of Rad51.Cell death & disease · 2022Article
- Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead.OncoTargets and therapy · 2022Review
- Article
- A Fibrinogen Alpha Fragment Mitigates Chemotherapy-InducedFrontiers in oncology · 2021Article
- A Novel Cell-Penetrating Antibody Fragment Inhibits the DNA Repair Protein RAD51.Scientific reports · 2019Article
- Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling.Advances in protein chemistry and structural biology · 2019Review
- Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy.Cell death & disease · 2018Article
- 53BP1 can limit sister-chromatid rupture and rearrangements driven by a distinct ultrafine DNA bridging-breakage process.Nature communications · 2018Article
- Enhancing Targeted Genomic DNA Editing in Chicken Cells Using the CRISPR/Cas9 System.PloS one · 2017Article
- Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells.Nucleic acids research · 2015Article
- A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.Cancer biology & therapy · 2015Article
- Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.Cancer research · 2014Article
- Targeting tumor suppressor networks for cancer therapeutics.Current drug targets · 2014Article
- A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin.Frontiers in oncology · 2014Article
- A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts.PloS one · 2014Article
- Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target.Translational research : the journal of laboratory and clinical medicine · 2013Review
- Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.EMBO molecular medicine · 2013Article
- Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Normal diploid cells have a limited replicative potential in culture, with progressively increasing interdivision time. Rarely, cell lines arise which can divide indefinitely; like tumor cells, such "immortal" lines display frequent chromosomal aberrations which may reflect high rates of recombination. Recombination frequencies within a plasmid substrate were 3.5-fold higher in nine immortal human cell lines than in six untransformed cell strains. Expression of HsRAD51, a human homolog of the yeast RAD51 and Escherichia coli recA recombinase genes, was 4.5-fold higher in immortal cell lines than in mortal cells. Stable transformation of human fibroblasts with simian virus 40 large T antigen prior to cell immortalization increased both chromosomal recombination and the level of HsRAD51 transcripts by two- to fivefold. T-antigen induction of recombination was efficiently blocked by introduction of HsRAD51 antisense (but not control) oligonucleotides spanning the initiation codon, implying that HsRAD51 expression mediates augmented recombination. Since p53 binds and inactivates HsRAD51, T-antigen-p53 association may block such inactivation and liberate HsRAD51. Upregulation of HsRAD51 transcripts in T-antigen-transformed and other immortal cells suggests that recombinase activation can also occur at the RNA level and may facilitate cell transformation to immortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.